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Abstract 
Background: The proportion of never‑smokers with non‑small cell lung cancer (NSCLC) is increasing, but that in 
Korea has not been well addressed in a large population. We aimed to evaluate the proportion and clinical features of 
never‑smokers with NSCLC in a large single institution.
Methods: We analyzed clinical data of 1860 consecutive patients who were newly diagnosed with NSCLC between 
June 2011 and December 2014.
Results: Of the 1860 NSCLC patients, 707 (38.0%) were never‑smokers. The proportions of women (83.7% vs. 5.6%) 
and adenocarcinoma (89.8% vs. 44.9%) were higher among never‑smokers than among ever‑smokers. Significantly 
more never‑smokers were diagnosed at a younger median age (65 vs. 68 years, P < 0.001) and earlier stage (stage I–II, 
44.5% vs. 38.9%, P = 0.015) compared with ever‑smokers. Epidermal growth factor receptor mutations (57.8% vs. 
24.4%, P < 0.001) and anaplastic lymphoma kinase rearrangements (7.8% vs. 2.8%, P < 0.001) were more common in 
never‑smokers, whereas Kirsten rat sarcoma viral oncogene homolog mutations (5.8% vs. 9.6%, P = 0.021) were less 
frequently encountered in never‑smokers than in ever‑smokers. Never‑smokers showed longer survival after adjust‑
ing for the favorable effects of younger age, female sex, adenocarcinoma histology, better performance status, early 
stage disease, being asymptomatic at diagnosis, received antitumor treatment, and the presence of driver mutations 
(hazard ratio, 0.624; 95% confidence interval, 0.460–0.848; P = 0.003).
Conclusions: More than one‑third of the Korean patients with NSCLC were never‑smokers. NSCLC in never‑smokers 
had different clinical characteristics and major driver mutations and resulted in longer overall survival compared with 
NSCLC in ever‑smokers.
Keywords: Non‑small cell lung carcinoma, Never‑smoker, Epidermal growth factor receptor, KRAS, Prognosis
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lung cancer is the leading cause of cancer death, account-
ing for an estimated 1.6 million deaths in 2012 worldwide 
[1]. In Korea, lung cancer has been the most common 
cause of cancer death since 1999 and was expected to 
account for 22.6% of all cancer deaths in 2012, although 
the age-standardized mortality due to lung cancer has 
decreased slightly in both men and women since 2002 
[2]. Lung cancer is considered a preventable cancer 
because tobacco smoking is the major cause of lung can-
cer [3]. According to comprehensive tobacco control pro-
grams, the incidence of lung cancer has been decreasing, 
whereas the proportion of never-smoking patients with 
non-small cell lung cancer (NSCLC) has been increasing 
[4, 5]. Global statistics estimate that overall 25% of lung 
cancers worldwide occur in never-smokers, and this pro-
portion is approximately 10%–15% in Western countries 
[6]. The percentage is higher in Eastern Asia, as stud-
ies from Japan [5] and Singapore [7] have reported that 
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never-smokers comprise approximately 32% of NSCLC 
patients.
It has been suggested that NSCLC in never-smokers 
should be regarded as a separate disease entity, as it 
bears striking differences from NSCLC in ever-smokers 
in terms of its epidemiologic and clinical characteristics; 
never-smokers with NSCLC are mostly women and have 
adenocarcinoma histology [5, 7, 8]. Recent molecular epi-
demiologic studies have supported that NSCLC in never-
smokers has distinct underlying molecular mechanisms. 
Epidermal growth factor receptor (EGFR) mutations and 
anaplastic lymphoma kinase (ALK) rearrangements are 
more frequent in never-smokers with NSCLC, whereas 
Kirsten rat sarcoma viral oncogene homolog (KRAS) 
mutations are associated with ever-smokers [9–11]. 
These genetic alterations occur in a mutually exclusive 
fashion, providing evidence that NSCLC in never-smok-
ers arises through different genetic pathways [8, 12].
Although there have been several studies reporting the 
clinical characteristics and prognosis of never-smoking 
NSCLC patients in Eastern Asia [5, 7], large-scale stud-
ies in the Korean population are lacking. This study was 
aimed to evaluate the proportion and clinical features of 




This study included all consecutive patients who were 
newly diagnosed with NSCLC at the Department of 
Internal Medicine, Seoul National University Hospital, 
Seoul, Republic of Korea between June 2011 and Decem-
ber 2014. Patients with recurred NSCLC were excluded. 
This study was approved by the institutional review board 
of the Seoul National University Hospital (H-1401-033-
548). The requirement for informed consent was waived.
Clinical and pathologic variables
All data were collected from medical records. Subjects 
were categorized based on the smoking status as never- 
and ever-smokers. An individual who had a lifetime expo-
sure of <100 cigarettes was defined as a never-smoker. 
An individual who smoked no <100 cigarettes during 
one’s lifetime was defined as an ever-smoker. The clinical 
and pathologic data reviewed for analysis included age, 
sex, symptoms at diagnosis, histologic subtype, Eastern 
Cooperative Oncology Group (ECOG) performance sta-
tus, disease stage, treatment received. Disease stage was 
defined as pathologic tumor, node, metastasis (TNM) 
stage for surgical cases and clinical TNM stage for non-
surgical cases at the time of initial diagnosis, according to 
the seventh edition of the American Joint Committee on 
Cancer Staging Manual [13].
Mutational analysis
DNA was extracted from formalin-fixed, paraffin-
embedded tissue as per the standard protocol. Initially, 
the EGFR mutation status (exons 18–21) and the KRAS 
mutation status (exon 2) of the extracted DNA were 
determined with nested polymerase chain reaction (PCR) 
followed by bidirectional direct sequencing, as previ-
ously described [14]. However, after peptide nucleic acid 
(PNA) clamping technology was recognized as a more 
sensitive method compared to direct sequencing for the 
detection of gene mutations in diagnostic specimens 
with a low proportion of tumor cells [15], PNA-medi-
ated real-time PCR clamping replaced direct sequencing 
since February 1, 2013. The PNAClamp EGFR Mutation 
Detection Kit (Panagene Inc., Daejeon, Korea) was used 
as previously described [15]. KRAS mutations in codons 
12 and 13 were detected with PNA-mediated real-time 
PCR. To test for ALK rearrangements, immunohisto-
chemistry (IHC) for ALK protein expression was used as 
a screening modality, and fluorescence in situ hybridiza-
tion (FISH) was used for confirmation. Unstained slides 
of formalin-fixed, paraffin-embedded tumor tissues were 
analyzed with FISH using the Vysis ALK Dual Color, 
Break Apart Rearrangement probe (Abbott Molecu-
lar, Abbott Park, IL, USA) as previously described [16]. 
ALK rearrangements were defined via split ALK 5′ and 3′ 
probe signals or isolated 3′ signals in more than 15% of 
scored tumor cells [17].
Follow‑up
The schedules of follow-up were determined by clini-
cians. Overall survival (OS) was measured from the date 
of diagnosis to the date of death or the date of last follow-
up. Death certificate data were obtained from the Korea 
National Statistical Office on 16 February 2015. The last 
follow-up was performed in February 2015.
Statistical analysis
Continuous data are presented as median (range), 
whereas categorical data are presented as numbers (per-
centages). Clinicopathologic variables between never-
smokers and ever-smokers were compared using the 
independent samples t test or the Mann–Whitney U test 
for continuous variables and the χ2 test or Fisher’s exact 
test for categorical variables. The OS rates were calcu-
lated according to the Kaplan–Meier method, and the 
differences among the groups were tested using the log-
rank test. Multivariate analysis was performed with the 
Cox proportional hazards model adjusting for variables 
with a P  <  0.2 in the univariate analysis. All statistical 
analyses were performed using Stata statistical software 
(Version 12.0, StataCorp LP, College Station, TX, USA).
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Results
Clinical characteristics
A total of 1860 NSCLC patients diagnosed during the 
study period were selected. Of the 1860 patients, 707 
(38.0%) were never-smokers, and 1153 (62.0%) were ever-
smokers. The characteristics of 1860 NSCLC patients 
according to smoking status are listed in Table  1. The 
median age at diagnosis of never-smokers was signifi-
cantly younger than that of ever-smokers (65 vs. 68 years, 
P < 0.001). A greater proportion of women were observed 
in the group of never-smokers than in the group of ever-
smokers (P  <  0.001), and the proportion of adenocarci-
noma was higher in never-smokers than in ever-smokers 
(P  <  0.001). Never-smokers had better ECOG perfor-
mance status (P < 0.001), tended to present with earlier 
stage disease (stage I–II, 44.5% vs. 38.9%, P = 0.015), and 
were more likely to be asymptomatic than ever-smokers 
(P < 0.001).
Frequencies of driver mutations according to smoking 
status
Of the 1860 patients, 1284 were tested for EGFR muta-
tions, 1288 were tested for ALK rearrangements, and 
1089 were tested for KRAS mutations. As expected, 
the frequencies of EGFR mutations (353/611 [57.8%] 
vs. 164/673 [24.4%]) and ALK rearrangements (47/605 
[7.8%] vs. 19/683 [2.8%]) were significantly higher in 
never-smokers than in ever-smokers (both P  <  0.001) 
(Table 1). Among the EGFR mutations, exon 19 deletions 
and exon 21 point mutations were significantly associated 
with never-smoking status (all P < 0.001), whereas muta-
tions in exons 18 and 20 were not (P = 0.227, P = 0.167, 
respectively).
Table 1 Characteristics of 1860 patients with NSCLC according to smoking status
NSCLC non-small cell lung cancer, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, KRAS Kirsten rat 
sarcoma viral oncogene homolog, ALK anaplastic lymphoma kinase
Variable Never‑smokers [cases (%)] Ever‑smokers [cases (%)] P
Total 707 (38.0) 1153 (62.0)
Sex <0.001
 Men 115 (16.3) 1088 (94.4)
 Women 592 (83.7) 65 (5.6)
Histologic subtype <0.001
 Adenocarcinoma 635 (89.8) 518 (44.9)
 Squamous cell carcinoma 25 (3.5) 483 (41.9)
 Others 47 (6.7) 152 (13.2)
ECOG PS <0.001
 0 379 (53.6) 427 (37.0)
 1 269 (38.1) 558 (48.4)
 2 43 (6.1) 131 (11.4)
 3 15 (2.1) 31 (2.7)
 4 1 (0.1) 6 (0.5)
Symptoms at diagnosis <0.001
 Asymptomatic 417 (59.0) 487 (42.2)
 Symptomatic 290 (41.0) 666 (57.8)
Driver mutations
 EGFR mutations (n = 1284) 353 (57.8) 164 (24.4) <0.001
 KRAS mutations (n = 1089) 29 (5.8) 57 (9.6) 0.021
 ALK rearrangements (n = 1288) 47 (7.8) 19 (2.8) <0.001
Stage <0.001
 I 261 (36.9) 295 (25.6)
 II 54 (7.6) 153 (13.3)
 III 115 (16.3) 293 (25.4)
 IV 277 (39.2) 412 (35.7)
Treatment <0.001
 Antitumor 654 (92.5) 983 (85.3)
 Supportive/unknown 53 (7.5) 170 (14.7)
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Of the 1089 NSCLC patients who were tested for KRAS 
mutations, 86 (7.9%) patients harbored a KRAS mutation. 
KRAS mutations were detected less frequently in never-
smokers than in ever-smokers (29/497 [5.8%] vs. 57/592 
[9.6%], P = 0.021) (Table 1). Of the 86 cases of KRAS muta-
tions, 6 were detected with PNA clamping at codon 12; 80 
were detected with direct sequencing (Table 2). Gly12Cys 
(28/80, 35.0%) was the most frequent KRAS mutation, 
followed by Gly12Asp (22/80, 27.5%) in Korean NSCLC 
patients. Of the 80 KRAS mutations, 27 (33.8%) were tran-
sition mutations. Gly12Asp was the most frequent KRAS 
mutation in never-smokers. The transition:transversion 
ratio of KRAS mutations was 12:15 for never-smokers and 
15:38 for ever-smokers (P = 0.149).
In the subgroup of 1153 patients with lung adenocar-
cinoma, the frequencies of EGFR mutations (341/570 
[59.8%] vs. 153/434 [35.3%], P  <  0.001) and ALK rear-
rangements (46/566 [8.1%] vs. 18/436 [4.1%], P = 0.010) 
were significantly higher in never-smokers than in ever-
smokers, whereas the frequency of KRAS mutations was 
significantly lower in never-smokers than in ever-smok-
ers (29/466 [6.2%] vs. 50/377 [13.3%], P < 0.001) (Fig. 1).
Survival analysis
The median follow-up time was 14.8  months (inter-
quartile range 6.2–26.6  months). A total of 675 deaths 
(36.3%) occurred during follow-up. Never-smokers 
showed longer survival than ever-smokers (Fig.  2). The 
median OS were not yet reached for never-smokers 
and was 23.9  months for ever-smokers (95% CI 19.9–
27.0 months). The 2-year OS rates were 75.8% for never-
smokers and 49.8% for ever-smokers (P < 0.001).
In addition to smoking status, the prognostic factors 
determined by univariate analyses were age, sex, histo-
logic subtype, ECOG performance status, disease stage, 
the presence of symptoms at diagnosis, EGFR mutations, 
KRAS mutations, ALK rearrangements, and treatment 
received. A multivariate analysis was performed with 
the Cox proportional hazards model including those 
factors, in which never-smoking status was associated 
with prolonged OS (hazard ratio [HR] 0.624; 95% CI 
0.460–0.848; P =  0.003) (Table  3). Younger age, adeno-
carcinoma histology, better performance status, earlier 
stage, being asymptomatic at diagnosis, and antitumor 
treatment were also independent favorable prognostic 
factors. EGFR mutations (HR 0.493; 95% CI 0.381–0.637; 
P  <  0.001) and ALK rearrangements (HR 0.397; 95% CI 
0.239–0.660; P < 0.001) were associated with prolonged 
OS, whereas KRAS mutations were associated with an 
increased risk of death (HR 1.560; 95% CI 1.085–2.243; 
P = 0.017).
Separate multivariate survival analyses were further 
conducted for 707 never-smokers and 1153 ever-smokers 
(Table  3). The histologic subtype, ECOG performance 
Table 2 Type and frequency of KRAS mutations according to smoking status in 80 patients with NSCLC
KRAS Kirsten rat sarcoma viral oncogene homolog, NSCLC non-small cell lung cancer
KRAS mutation Nucleotide substitution Amino acid substitution Never‑smokers [cases (%)] Ever‑smokers [cases (%)] Total [cases (%)]
Transversion GGT>TGT Gly12Cys 6 (22.2) 22 (41.5) 28 (35.0)
GGT>GTT Gly12Val 7 (25.9) 12 (22.6) 19 (23.8)
GGT>GCT Gly12Ala 2 (7.4) 3 (5.7) 5 (6.3)
GGT>TTT Gly12Phe 0 1 (1.9) 1 (1.3)
Transition GGT>GAT Gly12Asp 11 (40.7) 11 (20.8) 22 (27.5)
GGT>AGT Gly12Ser 0 2 (3.8) 2 (2.5)
GGC>GAC Gly13Asp 0 2 (3.8) 2 (2.5)
CAG>CGG Gln22Arg 1 (3.7) 0 1 (1.3)
Total 27 53 80
Fig. 1 Frequencies of driver mutations in 1153 patients with lung 
adenocarcinoma according to smoking status. EGFR epidermal 
growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene 
homolog, ALK anaplastic lymphoma kinase. n is the number of 
patients with lung adenocarcinoma who were tested for each muta‑
tion
Page 5 of 7Cho et al. Chin J Cancer  (2017) 36:20 
status, disease stage, treatment received, and status of 
EGFR mutations were common prognostic factors in 
both never- and ever-smokers. However, younger age and 
being asymptomatic at diagnosis were no longer associ-
ated with prolonged OS in never-smokers. In ever-smok-
ers, KRAS mutations and ALK rearrangements were not 
independent prognostic factors for OS.
Discussion
In the current study, we summarized the clinical charac-
teristics and major driver mutations of NSCLC patients 
and compared survival outcomes between never- and 
ever-smokers in 1860 Korean NSCLC patients. We pro-
vided the profile of major genes (EGFR, KRAS, and ALK), 
and we adjusted for the presence of each driver mutation 
in the survival analysis. Never-smokers accounted for 
38.0% of the NSCLC patients, and smoking status was 
an independent prognostic factor regardless of whether 
NSCLC patients had oncogenic driver mutations.
In our study, never-smokers were diagnosed at an ear-
lier age than ever-smokers, which was consistent with a 
previous report from Singapore [7]. However, several 
studies from Western countries reported the opposite 
observation: never-smokers were diagnosed at a simi-
lar or older age than ever-smokers [4, 18]. This might be 
explained by later ages of initiation of smoking in Asian 
smokers than in Western smokers; because the age at 
smoking onset in Asian countries is much older than 
that in Western countries, the age at cancer diagnosis for 
Asian smokers may be older. In addition, the great con-
tribution of risk factors other than smoking might affect 
the development of lung cancer in Asian countries [19]. 
Another interesting observation was that never-smokers 
tended to present disease at an early stage. This find-
ing was consistent with the result of a study performed 
in Japan [5], whereas studies from Singapore [7] and the 
United States [20] reported that never-smokers were 
more likely to present with advanced disease and another 
study from the United States found no differences [18].
Although EGFR mutations have been well known as 
the most common genetic alteration in never-smoking 
NSCLC patients, EGFR mutations were detected in 24.4% 
of ever-smoking NSCLC patients in our study. The fre-
quencies of EGFR mutations in ever-smokers vary widely, 
from 8.4% to 11.9% in Europe and North America to 
26.0%–35.9% in Japan and China [21]. Several potential 
risk factors other than EGFR mutations in never-smokers 
have been proposed, including environmental tobacco 
smoke, residential radon, asbestos exposure, cooking oil 
fumes, genetic susceptibility, hormone factors, and onco-
genic viruses, which may contribute with varied degrees 
in line with sex and geographical areas [8].
In the present study, Gly12Cys, resulting from a codon 
12 GGT>TGT substitution, was the most frequent sub-
type of KRAS mutations, which was consistent with the 
results of studies in Western countries [22, 23]. How-
ever, a recent study analyzing 82 KRAS mutations in 
1420 Korean NSCLC patients reported that Gly12Asp, 
resulting from a codon 12 GGT>GAT substitution, was 
the most frequent KRAS substitution [24]. In contrast to 
the previous studies showing that never-smokers were 
more likely to have a transition mutation rather than a 
transversion mutation [22, 24], the association between 
never-smoking status and transition mutations was not 
statistically significant in our cohort (P = 0.149). Because 
the frequency of KRAS mutations in the Asian popula-
tion is relatively low, our study lacked the power to reach 
any firm conclusions about distinct characteristics of 
KRAS mutation in the Korean population even though 
the study included over one thousand NSCLC patients 
who were tested for KRAS mutations.
Our study has several limitations, such as its retro-
spective design, and the fact that it was conducted at a 
single institution. However, our institution is a 1750-bed 
tertiary teaching hospital and a large referral center in 
Korea. Moreover, we recruited all consecutive patients 
with newly diagnosed NSCLC during the study period 
to minimize the selection bias. The major limitation of 
this study was that the information regarding adminis-
tration of specific targeted agents was not available. The 
use of targeted therapy may be a confounding factor of 
inherent mutation status in predicting survival. Another 
limitation was the relatively short follow-up period. In 
addition, information about exposure to risk factors 
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Fig. 2 Kaplan‑Meier overall survival curves of 1860 patients with 
non‑small cell lung cancer (NSCLC) according to smoking status
Page 6 of 7Cho et al. Chin J Cancer  (2017) 36:20 
needed to elucidate the potential risk factors for NSCLC 
in never-smokers.
Conclusions
In summary, more than one-third of Korean patients 
with NSCLC were never-smokers. We showed distinct 
features of NSCLC in Korean never-smokers compared 
with ever-smokers, including a better prognosis in 
never-smokers. After adjusting for the favorable effects 
of younger age, better performance status, earlier stage 
of disease, being asymptomatic at diagnosis, and the 
presence of driver mutations, the association between 
never-smoking status and prolonged survival became 
apparent.
Table 3 Multivariate analysis of overall survival using the Cox regression in 1860 patients with NSCLC
NSCLC non-small cell lung cancer, HR hazard ratio, CI confidence interval, NA not applicable, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR 
epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene homolog, ALK anaplastic lymphoma kinase
a Age was used as a continuous variable
b The individuals who did not undergo testing for each mutation were included in the multivariate analysis, however, the data are not shown
Variable Whole cohort (n = 1860) Never‑smokers (n = 707) Ever‑smokers (n = 1153)
HR 95% CI P HR 95% CI P HR 95% CI P
Smoking status NA NA
 Ever‑smoker 1.000
 Never‑smoker 0.624 0.460–0.848 0.003
Agea 1.023 1.014–1.032 <0.001 1.005 0.988–1.021 0.582 1.029 1.018–1.040 <0.001
Sex
 Male 1.000 1.000 1.000
 Female 1.054 0.780–1.426 0.731 0.977 0.619–1.544 0.922 1.179 0.794–1.750 0.414
Histologic subtype
 Adenocarcinoma 1.000 1.000 1.000
 Squamous cell carcinoma 1.387 1.115–1.727 0.003 2.262 1.131–4.523 0.021 1.295 1.019–1.645 0.035
 Others 1.506 1.184–1.915 0.001 1.066 0.618–1.839 0.818 1.586 1.201–2.095 0.001
ECOG PS
 0–1 1.000 1.000 1.000
 2–4 2.098 1.725–2.552 <0.001 2.743 1.732–4.343 <0.001 1.976 1.589–2.457 <0.001
Symptoms at diagnosis
 Asymptomatic 1.000 1.000 1.000
 Symptomatic 0.722 0.610–0.854 <0.001 0.715 0.503–1.015 0.061 0.737 0.608–0.894 0.002
EGFR mutationsb
 Absent 1.000 1.000 1.000
 Present 0.493 0.381–0.637 <0.001 0.516 0.352–0.757 0.001 0.459 0.314–0.671 <0.001
KRAS mutationsb
 Absent 1.000 1.000 1.000
 Present 1.560 1.085–2.243 0.017 2.540 1.253–5.150 0.010 1.416 0.921–2.176 0.113
ALK rearrangementsb
 Absent 1.000 1.000 1.000
 Present 0.397 0.239–0.660 <0.001 0.225 0.105–0.484 <0.001 0.723 0.362–1.444 0.358
Stage
 I 1.000 1.000 1.000
 II 2.087 1.387–3.143 <0.001 3.995 1.365–11.694 0.011 1.810 1.163–2.818 0.009
 III 4.323 3.095–6.039 <0.001 4.470 1.872–10.671 0.001 4.036 2.797–5.824 <0.001
 IV 10.314 7.507–14.172 <0.001 23.067 10.840–49.085 <0.001 8.437 5.908–12.049 <0.001
Treatment
 Supportive/unknown 1.000 1.000 1.000
 Antitumor 0.634 0.516–0.780 <0.001 0.377 0.214–0.662 0.001 0.678 0.541–0.849 0.001
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